Safety and preliminary clinical activity of JNJ-63898081 (JNJ-081), a PSMA and CD3 bispecific antibody, for the treatment of metastatic castrate-resistant prostate cancer (mCRPC).

被引：12
|
作者：
Lim, Emerson A.
Schweizer, Michael Thomas
Chi, Kim N.
Aggarwal, Rahul Raj
Agarwal, Neeraj
Gulley, James L.
Attiyeh, Edward F.
Greger, James
Wu, Shujian
Jaiprasart, Pharavee
Loffredo, John
Bandyopadhyay, Nibedita
Xie, Hong
Hansen, Aaron Richard
机构：
[1] Columbia Univ, Med Ctr, New York, NY USA
[2] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA
[3] Univ British Columbia, BC Canc Agcy, Vancouver, BC, Canada
[4] UCSF, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
[5] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
[6] NCI, NIH, Bethesda, MD 20892 USA
[7] Janssen Res & Dev, Spring House, PA USA
[8] Janssen Res & Dev, Horsham, PA USA
[9] Janssen Res & Dev, Raritan, NJ USA
[10] Janssen Res & Dev LLC, Spring House, PA USA
[11] Princess Margaret Canc Ctr, Toronto, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 06期
关键词：
D O I：
10.1200/JCO.2022.40.6_suppl.279
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
279
引用
收藏
页数：3
相关论文
共 28 条
  • [21] The Outcome and Safety of Re-challenge Lutetium-177 PSMA (177Lu-PSMA) Therapy with Low-Dose Docetaxel as a Radiosensitizer-a Promising Combination in Metastatic Castrate-Resistant Prostate Cancer (mCRPC): a Case Report
    Maharaj, Masha
    Heslop, Lucille
    Govender, Trisha
    Korowlay, Nisaar
    Singh, Aviral
    Choudhary, Partha
    Sathekge, Mike
    NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 55 (03) : 136 - 140
  • [22] Abiraterone acetate with prednisone and cabazitaxel as subsequent treatment after first-line docetaxel in metastatic castrate-resistant prostate cancer (mCRPC): Final efficacy and safety analysis of the CAPRO study.
    del Alba, Arancha Gonzalez
    Puente, Javier
    Sala, Nuria
    Mendez, Maria Jose
    Pinto, Alvaro
    Sanchez, Angel Rodriguez
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [23] Overall survival (OS) analysis of a phase II study using a pox viral-based vaccine, PSA-TRICOM, in the treatment of metastatic, castrate-resistant prostate cancer (mCRPC): Implications for clinical trial design
    Madan, R. A.
    Gulley, J. L.
    Dahut, W. L.
    Tsang, K. Y.
    Steinberg, S. M.
    Schlom, J.
    Arlen, P. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [24] Phase 1 clinical trial of AMG 340, a prostate-specific membrane antigen (PSMA)-targeted T-cell engager with a novel low-affinity CD3 binding domain designed to mitigate toxicity for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
    Falchook, Gerald Steven
    McKean, Meredith
    Kelly, William Kevin
    Patel, Manish R.
    Bupathi, Manojkumar
    Liaw, Bobby Chi-Hung
    Garmezy, Benjamin
    Vuu, Irene
    Smith, Kristen
    Lolkema, Martijn
    Fong, Lawrence
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [25] Preliminary efficacy and safety results from the (TATCIST) trial: A PSMA-directed targeted alpha therapy with FPI-2265 (225Ac-PSMA-I&T) for the treatment of metastatic castration-resistant prostate cancer (mCRPC)
    Delpassand, Ebrahim S.
    Hashmi, Mohammad Jawed
    Kazakin, Julia
    Nawaz, Omer
    Garufi, Gabriella
    Schindler, Joanne
    Nordquist, Luke
    CANCER RESEARCH, 2024, 84 (07)
  • [26] A phase Ib open-label, dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with abiraterone or enzalutamide in metastatic castrate-resistant prostate cancer.
    Vaishampayan, Ulka N.
    Narayan, Vivek
    Wise, David
    Lang, Joshua Michael
    Lowentritt, Benjamin H.
    Mellado, Begona
    Carles, Joan
    Saez, M. Isabel
    Abida, Wassim
    Taplin, Mary-Ellen
    Azad, Arun
    Wang, Karrie
    Barbash, Olena
    Ferron-Brady, Geraldine
    Fecteau, Doug
    Khaled, Ahmed Hussein
    Dhar, Arindam
    De Bono, Johann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [27] ARC-6: A phase 1b/2, open-label, randomized platform study to evaluate efficacy and safety of etrumadenant (AB928)-based treatment combinations in patients with metastatic castrate-resistant prostate cancer (mCRPC).
    Subudhi, Sumit Kumar
    Bendell, Johanna C.
    Carducci, Michael Anthony
    Kopp, Lisa M.
    Scott, Jennifer
    Grady, Michele M.
    Gardner, Olivia
    Wise, David R.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [28] Phase Ia and lb studies of the novel carcinoembryonic antigen (CEA) 1-cell bispecific (CEA CD3 TCB) antibody as a single agent and in combination with atezolizumab: Preliminary efficacy and safety in patients with metastatic colorectal cancer (mCRC).
    Tabernero, Josep
    Melero, Ignacio
    Ros, Willeke
    Argiles, Guillem
    Marabelle, Aurelien
    Rodriguez-Ruiz, Maria E.
    Albanell, Joan
    Calvo, Emiliano
    Moreno, Victor
    Cleary, James M.
    Eder, Joseph Paul
    Karanikas, Vaios
    Bouseida, Said
    Sandoval, Federico
    Sabanes, Daniel
    Sreckovic, Sasha
    Hurwitz, Herbert
    Paz-Ares, Luis G.
    Suarez, Jose M. Saro
    Segal, Neil Howard
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
123